LADENBURG THALM/SH SH upgraded shares of United Therapeutics (NASDAQ:UTHR) from a neutral rating to a buy rating in a research report released on Thursday morning, BenzingaRatingsTable reports. LADENBURG THALM/SH SH currently has $106.00 target price on the biotechnology company’s stock, up from their previous target price of $103.00.
Other analysts have also recently issued research reports about the company. Jefferies Financial Group raised United Therapeutics from an underperform rating to a hold rating and set a $90.00 price objective for the company in a research report on Thursday. Oppenheimer lowered their price objective on United Therapeutics from $160.00 to $155.00 and set an outperform rating for the company in a research report on Tuesday, April 9th. UBS Group raised United Therapeutics from a sell rating to a neutral rating and lowered their price target for the stock from $115.00 to $94.00 in a research report on Friday, May 17th. They noted that the move was a valuation call. Wedbush set a $273.00 price target on United Therapeutics and gave the stock a buy rating in a research report on Wednesday, May 8th. Finally, Cowen reaffirmed a hold rating and set a $103.00 price target on shares of United Therapeutics in a research report on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $123.80.
Shares of United Therapeutics stock traded up $0.19 during trading on Thursday, reaching $83.26. The company’s stock had a trading volume of 459,000 shares, compared to its average volume of 560,459. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.84 and a current ratio of 7.19. The stock has a market capitalization of $3.48 billion, a P/E ratio of 6.22 and a beta of 1.04. United Therapeutics has a 1-year low of $74.31 and a 1-year high of $130.00. The company has a 50-day moving average price of $78.12.
In other United Therapeutics news, Director Raymond Dwek sold 3,750 shares of United Therapeutics stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $76.11, for a total transaction of $285,412.50. Following the completion of the transaction, the director now owns 3,750 shares in the company, valued at approximately $285,412.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard Giltner sold 5,000 shares of United Therapeutics stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $79.05, for a total value of $395,250.00. Following the transaction, the director now owns 5,000 shares of the company’s stock, valued at approximately $395,250. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its stake in shares of United Therapeutics by 2.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,088,982 shares of the biotechnology company’s stock worth $118,583,000 after acquiring an additional 29,427 shares during the period. Bank of America Corp DE boosted its stake in United Therapeutics by 0.8% during the fourth quarter. Bank of America Corp DE now owns 93,345 shares of the biotechnology company’s stock valued at $10,165,000 after buying an additional 706 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in United Therapeutics by 6.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 11,060 shares of the biotechnology company’s stock valued at $1,204,000 after buying an additional 630 shares during the last quarter. Legal & General Group Plc boosted its stake in United Therapeutics by 11.6% during the fourth quarter. Legal & General Group Plc now owns 112,631 shares of the biotechnology company’s stock valued at $12,265,000 after buying an additional 11,664 shares during the last quarter. Finally, Norges Bank bought a new position in United Therapeutics during the fourth quarter valued at approximately $54,233,000. Hedge funds and other institutional investors own 95.37% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
See Also: What is a Call Option?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.